NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Cybin D/B/A Helus Pharma (HELP) Stock Analysis

Cybin D/B/A Helus Pharma (HELP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

HELP

$12.22

+$0.45 (+3.82%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare HELP with… →

HELP Key Statistics

As of Sep 4, 2026
Trading
Open
$11.81
Previous Close
$11.77
Day's Range
11.44–12.26
52-Week Range
3.76–14.35
Volume
1.02M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.63
Valuation
Market Cap
$892.80M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.20
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$148.00M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
73.06M
1-Year Return
+104.35%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
1.66M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

HELP Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+49.39%
2025−7.26%
2024−43.39%
2023+38.05%
2022−75.25%
2021−19.46%
2020+13.27%
2019 (partial year)+0.00%

As of September 4, 2026.

HELP Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$148.00M—
2024$0.00−$81.61M—
2023$0.00−$78.08M—
2022$0.00−$47.49M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$142.59M−$148.00M—
2024$0.00—−$103.13M−$81.61M—
2023$0.00—−$78.84M−$78.08M—
2022$0.00—−$51.52M−$47.49M—

Annual figures as reported, in the company's reporting currency. As of March 31, 2026.

HELP Valuation vs Biotechnology Median

Median of 656 stocks
MetricHELPBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Cybin D/B/A Helus Pharma (HELP) carries a market capitalisation of $892.80M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 100.

The most recent close on file for HELP is $12.22, dated September 4, 2026. That is +$0.45 (+3.82%) against the previous close. The 52-week range on file runs from $3.76 to $14.35. The latest close sits 225% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $148.00M. The reported profit margin is 0%. Trailing earnings per share are −4.2.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year price return is +104.35%. Across 5 years the annualized return works out at −34.36%. The reported beta is 0.63. Daily returns over the trailing 7 years annualize to a volatility of 332.96%.

Growth & Income

The record shows no dividend for HELP.

So far in 2026 the price is +49.39%. The strongest complete calendar year on file is 2023 at +38.05%; the weakest is 2022 at −75.25%. Of the 6 complete calendar years on file, 2 finished higher.

Peer Comparison

Cybin D/B/A Helus Pharma (HELP) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cybin D/B/A Helus Pharma HELP $892.80M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Cybin D/B/A Helus Pharma has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Cybin D/B/A Helus Pharma

Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.

Visit website →